Table 1.

Prospective studies of extreme hypofractionation in patients with localized low- and intermediate-risk PCa.

Reference	Risk Group	N Patients	RT Regimen (Gy)	Biochemical Failure-Free Survival	≥3 Acute Toxicity (%)	≥3 Chronic Toxicity (%)
[10]	Low-Risk	40	5 fr × 6.5	90% at 2 years	GU 2.5% GI 0%	GU 0% GI 0%
[18]	Low-Risk	45	5 fr × 7.5 5 fr × 7.25	92.7% at 5 years	GU 2% GI 0%	GU 1% GI 5%
[19]	Low-Risk	84	5 fr × 7	93% at 5 years	GU 1% GI 0%	GU 1% GI 1%
[20]	Low-Risk Intermediate-Risk	91	5 fr × 9 5 fr × 9.5 5 fr × 1	98.6% at 5 years	GU 0% GI 2%	GU 5,5% GI 7%
[11]	Low-Risk Intermediate-Risk	259	4 fr × 9.5	100% LR, 88.5% IR at 5 years	GU 1.1% GI 0%	GU 1.9% GI 0%
[12]	Intermediate-Risk	350	5 fr × 8	97.1% at 5 years	GU 0% GI 0%	GU 1.3% GI 0%
[13]	Low-Risk Intermediate-Risk	136	5 fr × 6.5 5 fr × 7 5 fr × 7.5 5 fr × 8	NR	GU 0% GI 0%	GU 0.7% GI 0%
[15]	Low-Risk Intermediate-Risk	30	2 fr × 13	96.7% at 5 years	GU 0% GI 0%	GU 3.3% GI 3.3%
[16]	Low-Risk Intermediate-Risk	152	5 fr × 8	95.7% at 5 years	NR	NR

Abbreviations: LR, low-risk; fr, fractions; GI, gastrointestinal; GU, genitourinary; NR, not reported; IR, intermediate-risk; RT, radiotherapy.